1. GibsonPR, DudleyFJ. Ischemic hepatitis: clinical features, diagnosis and prognosis. Aust N Z J Med1984;14:822. CrossRef

2. HenrionJ, MinetteP, ColinL, et al.Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case‐controlled, hemodynamic study of 17 consecutive cases. Hepatology1999;29:427. CrossRef

3. SeetoRK, FennB, RockeyDC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med2000;109:109. CrossRef

4. GitlinN, SerioKM. Ischemic hepatitis: widening horizon. Am J Gastroenterol1992;87:831.

5. CassidyWM, ReynoldsTB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol1994;19:118. CrossRef

6. HenrionJ, SchapiraM, HellerFR. Ischemic hepatitis: the need for precise criteria (letter). J Clin Gastroenterol1996;23:305. CrossRef

7. GiallourakisCC, RosenbergPM, FriedmanLS. The liver in heart failure. Clin Liver Dis2002;6:947. CrossRef

8. HenrionJ, SchapiraM, LuwaertR, et al.Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine2003;82:392. CrossRef

9. de FranchisR. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol2010;53:762. CrossRef

10. JanssenHL, Garcia‐PaganJC, EliasE, et al.Budd‐Chiari syndrome: a review by an expert panel. J Hepatol2003;38:364. CrossRef

11. DeLeveLD, VallaDC, Garcia‐TsaoG. Vascular disorders of the liver. Hepatology2009;49:1729. CrossRef

12. KageM, ArakawaM, KojiroM, et al.Histopathology of membranous obstruction of the inferior vena cava in the Budd‐Chiari syndrome. Gastroenterology1992;102:2081.

13. ShresthaSM, JoshiBL, ShresthaS, et al.Cavographic study of inferior vena cava obstruction. Cavographic study of an early stage of obstruction of the hepatic portion of the inferior vena cava. J Gastroenterol Hepatol2000;15:202. CrossRef

14. DenningerMH, ChaitY, CasadevallN, et al.Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology2000;31:587. CrossRef

15. JanssenHL, MeinardiJR, VleggaarFP, et al.Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd‐Chiari syndrome and portal vein thrombosis: results of a case‐control study. Blood2000;96:2364.

16. Darwish MuradS, PlessierA, Hernandez‐GuerraM, et al.Etiology, management, and outcome of the Budd‐Chiari syndrome. Ann Intern Med2009;151:167. CrossRef

17. VallaD, CasadevallN, LacombeC, et al.Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd‐Chiari syndrome. Ann Intern Med1985;103:329. CrossRef

18. VallaD, CasadevallN, HuisseMG, et al.Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology1988;94:1063.

19. De StefanoV, TeofiliL, LeoneG, et al.Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd‐Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost1997;23:411. CrossRef

20. PrimignaniM, MannucciPM. The role of thrombophilia in splanchnic vein thrombosis. Semin Liver Dis2008;28:293. CrossRef

21. BismuthE, HadengueA, HammelP, et al.Hepatic vein thrombosis in Behcet's disease. Hepatology1990;11:969. CrossRef

22. SaatciI, OzmenM, BalkanciF, et al.Behcet's disease in the etiology of Budd‐Chiari disease. Angiology1993;44:392. CrossRef

23. de BruijneEL, Darwish MuradS, de MaatMP, et al.Genetic variation in thrombin‐activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost2007;97:181.

24. HoekstraJ, GuimaraesAH, LeebeekFW, et al.Impaired fibrinolysis as a risk factor for Budd‐Chiari syndrome. Blood2010;115:388. CrossRef

25. TalensS, HoekstraJ, DirkxSP, et al.Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd‐Chiari syndrome. J Hepatol2011;54:908. CrossRef

26. YoungRC. The Budd‐Chiari syndrome caused by Aspergillus; two patients with vascular invasion of the hepatic veins. Arch Intern Med1969;124:754. CrossRef

27. Darwish MuradS, VallaDC, de GroenPC, et al.Determinants of survival and the effect of portosystemic shunting in patients with Budd‐Chiari syndrome. Hepatology2004;39:500. CrossRef

28. OkudaH, YamagataH, ObataH, et al.Epidemiological and clinical features of Budd‐Chiari syndrome in Japan. J Hepatol1995;22:1. CrossRef

29. DilawariJB, BamberyP, ChawlaY, et al.Hepatic outflow obstruction (Budd‐Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore)1994;73:21. CrossRef

30. Cazals‐HatemD, VilgrainV, GeninP, et al.Arterial and portal circulation and parenchymal changes in Budd‐Chiari syndrome: a study in 17 explanted livers. Hepatology2003;37:510. CrossRef

31. Darwish MuradS, VallaDC, de GroenPC, et al.Pathogenesis and treatment of Budd‐Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol2006;101:83. CrossRef

32. MahmoudAEA, HelmyAS, BillinghamS, et al.Poor prognosis and limited therapeutic options in patients with Budd‐Chiari syndroem and portal venous system thrombosis. Eur J Gastroenterol Hepatol1997;9:485. CrossRef

33. TanakaM, WanlessIR. Pathology of the liver in Budd‐Chiari syndrome: portal vein thrombosis and the histogenesis of veno‐centric cirrhosis, veno‐portal cirrhosis, and large regenerative nodules. Hepatology1998;27:488. CrossRef

34. HadengueA, PoliquinM, VilgrainV, et al.The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology1994;106:1042.

35. MillerWJ, FederleMP, StraubWH, et al.Budd‐Chiari syndrome: imaging with pathologic correlation. Abdom Imaging1993;18:329. CrossRef

36. FlorN, ZuinM, BrovelliF, et al.Regenerative nodules in patients with chronic Budd‐Chiari syndrome: a longitudinal study using multiphase contrast‐enhanced multidetector CT. Eur J Radiol2010;73:588. CrossRef

37. MoucariR, RautouPE, Cazals‐HatemD, et al.Hepatocellular carcinoma in Budd‐Chiari syndrome: characteristics and risk factors. Gut2008;57:828. CrossRef

38. ParkH, YoonJY, ParkKH, et al.Hepatocellular carcinoma in Budd‐Chiari syndrome: a single center experience with long‐term follow‐up in South Korea. World J Gastroenterol2012;18:1946. CrossRef

39. Hernandez‐GuerraM, LopezE, BellotP, et al.Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome. Hepatology2006;43:27. CrossRef

40. ChaitY, CondatB, Cazals‐HatemD, et al.Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol2005;129:553. CrossRef

41. DayalS, PatiHP, PandeGK, et al.Multilineage hemopoietic stem cell defects in Budd Chiari syndrome. J Hepatol1997;26:293. CrossRef

42. HirshbergB, ShouvalD, FibachE, et al.Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd‐Chiari syndrome. J Hepatol2000;32:574. CrossRef

43. PrimignaniM, BarosiG, BergamaschiG, et al.Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology2006;44:1528. CrossRef

44. KiladjianJJ, CervantesF, LeebeekFW, et al.The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood2008;111:4922. CrossRef

45. SmalbergJH, MuradSD, BraakmanE, et al.Myeloproliferative disease in the pathogenesis and survival of Budd‐Chiari syndrome. Haematologica2006;91:1712.

46. PatelRK, LeaNC, HeneghanMA, et al.Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd‐Chiari syndrome. Gastroenterology2006;130:2031. CrossRef

47. TefferiA, ThieleJ, OraziA, et al.Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood2007;110:1092. CrossRef

48. BittencourtPL, CoutoCA, RibeiroDD. Portal vein thrombosis and Budd‐Chiari syndrome. Clin Liver Dis2009;13:127. CrossRef

49. TefferiA, SolbergLA, SilversteinMN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med2000;109:141. CrossRef

50. FruchtmanSM, MackK, KaplanME, et al.From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol1997;34:17.

51. CortelazzoS, FinazziG, RuggeriM, et al.Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med1995;332:1132. CrossRef

52. RautouPE, AngermayrB, Garcia‐PaganJC, et al.Pregnancy in women with known and treated Budd‐Chiari syndrome: maternal and fetal outcomes. J Hepatol2009;51:47. CrossRef

53. SharmaS, TexeiraA, TexeiraP, et al.Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol2004;40:172. CrossRef

54. ZhangCQ, FuLN, XuL, et al.Long‐term effect of stent placement in 115 patients with Budd‐Chiari syndrome. World J Gastroenterol2003;9:2587.

55. DeLeveLD, KanelGC. Vascular diseases of the liver. In: YamadaT, AlpersDH, KaplowitzN, et al. (eds). Atlas of Gastroenterology, 4th ed. Oxford: Blackwell Publishing; 2009: 731. CrossRef

56. Hernandez‐GuerraM, TurnesJ, RubinsteinP, et al.PTFE‐covered stents improve TIPS patency in Budd‐Chiari syndrome. Hepatology2004;40:1197. CrossRef

57. PerelloA, Garcia‐PaganJC, GilabertR, et al.TIPS is a useful long‐term derivative therapy for patients with Budd‐ Chiari syndrome uncontrolled by medical therapy. Hepatology2002;35:132. CrossRef

58. BachetJB, CondatB, HagegeH, et al.Long‐term portosystemic shunt patency as a determinant of outcome in Budd‐Chiari syndrome. J Hepatol2007;46:60. CrossRef

59. MenthaG, GiostraE, MajnoPE, et al.Liver transplantation for Budd‐Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol2006;44:520. CrossRef

60. SegevDL, NguyenGC, LockeJE, et al.Twenty years of liver transplantation for Budd‐Chiari syndrome: a national registry analysis. Liver Transpl2007;13:1285. CrossRef

61. Garcia‐PaganJC, Hernandez‐GuerraM, BoschJ. Extrahepatic portal vein thrombosis. Semin Liver Dis2008;28:282. CrossRef

62. PlessierA, Darwish‐MuradS, Hernandez‐GuerraM, et al.Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow‐up study. Hepatology2010;51:210. CrossRef

63. VallaD, CondatB. Portal vein thrombosis in adults: pathophysiology, pathogenesis, and management. J Hepatol2000;32:865. CrossRef

64. RosenbergRD, AirdWC. Vascular‐bed–specific hemostasis and hypercoagulable states. N Engl J Med1999;340:1555. CrossRef

65. TurnesJ, Garcia‐PaganJC, GonzalezM, et al.Portal hypertension‐related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol2008;6:1412. CrossRef

66. BachAM, HannLE, BrownKT, et al.Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology1996;201:149. CrossRef

67. MathieuD, VasileN, GrenierP. Portal thrombosis. Dynamic CT features and course. Radiology1985;154:737. CrossRef

68. CondatB, PessioneF, Helene DenningerM, et al.Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology2000;32:466. CrossRef

69. KumarS, SarrMG, KamathPS. Mesenteric venous thrombosis. N Engl J Med2001;345:1683. CrossRef

70. GuptaD, VijayaDR, GuptaR, et al.Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol2001;96:3395. CrossRef

71. LlopE, de JuanC, SeijoS, et al.Portal cholangiopathy: radiological classification and natural history. Gut2011;60:853. CrossRef

72. FanelliF, AngeloniS, SalvatoriFM, et al.Transjugular intrahepatic portosystemic shunt with expanded‐polytetrafuoroethylene‐covered stents in non‐cirrhotic patients with portal cavernoma. Dig Liver Dis2011;43:78. CrossRef

73. QiX, HanG, YinZ, et al.Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non‐cirrhotic patients. Dig Dis Sci2012;57:1072. CrossRef

74. CondatB, PessioneF, HillaireS, et al.Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology2001;120:490. CrossRef

75. KitchensCS, WeidnerMH, LottenbergR. Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe. J Thromb Thrombolysis2007.

76. OrrDW, HarrissonPM, KaraniJ, et al.Chronic portomesenteric and portosplenomesenteric venous thrombosis: evaluation of long term follow‐up and determinants of survival. Hepatology2005;42:212A.

77. DumortierJ, VaillantE, BoillotO, et al.Diagnosis and treatment of biliary obstruction caused by portal cavernoma. Endoscopy2003;35:446. CrossRef

78. LucaA, MiragliaR, CarusoS, et al.Short‐ and long‐term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut2011;60:846. CrossRef

79. SenzoloM, TibbalsJ, CholongitasE, et al.Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther2006;23:767. CrossRef

80. BrasG, JeliffeDB, StuartKL. Veno‐occlusive disease of the liver with non‐portal type of cirrhosis occurring in Jamaica. Arch Pathol1954;57:285.

81. ShulmanHM, FisherLB, SchochHG, et al.Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology1994;19:1171. CrossRef

82. RollinsBJ. Hepatic veno‐occlusive disease. Am J Med1986;81:297. CrossRef

83. DeLeveLD, McCuskeyRS, WangX, et al.Characterization of a reproducible rat model of hepatic veno‐occlusive disease. Hepatology1999;29:1779. CrossRef

84. DeLeveLD, ItoY, MachenNW, et al.Embolization by sinusoidal lining cells causes the congestion of hepatic venoocclusive disease. Gastroenterology2000;118:A2345. CrossRef

85. DeLeveLD, ShulmanHM, McDonaldGB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis2002;22:623. CrossRef

86. DeLeveLD. Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther1994;268:1261.

87. DeLeveLD, WangX, KuhlenkampJF, et al.Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology1996;23:589. CrossRef

88. DeLeveLD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology1996;24:830. CrossRef

89. DeLeveLD, WangX, TsaiJ, et al.Prevention of sinusoidal obstruction syndrome (hepatic venoocclusive disease) in the rat by matrix metalloproteinase inhibitors. Gastroenterology2003;125:882. CrossRef

90. DeLeveLD, WangX, KanelGC, et al.Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology2003;38:900. CrossRef

91. ShulmanHM, McDonaldGB, MatthewsD, et al.An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology1980;79:1178.

92. McDonaldGB, HindsMS, FisherLD, et al.Veno‐occlusive disease of the liver and multiorgan failure after bone marrow transplantation – a cohort study of 355 patients. Ann Intern Med1993;118:255. CrossRef

93. JonesRJ, LeeKSK, BeschornerWE, et al.Veno‐occlusive disease of the liver following bone marrow transplantation. Transplantation1987;44:778. CrossRef

94. HaboubiNY, AliHH, WhitwellHL, et al.Role of endothelial cell injury in the spectrum of azathioprine‐induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol1988;83:256.

95. SterneckM, WiesnerR, AscherN, et al.Azathioprine hepatotoxicity after liver transplantation. Hepatology1991;14:806. CrossRef

96. GaneE, PortmannB, SaxenaR, et al.Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology1994;20:88. CrossRef

97. KatzkaDA, SaulSH, JorkaskyD, et al.Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology1986;90:446.

98. EisenhauerT, HartmannH, RumpfKW, et al.Favourable outcome of hepatic veno‐occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature. Digestion1984;30:185. CrossRef

99. KaoNL, RosenblateHJ. 6‐thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol1993;28:1017. CrossRef

100. DeLeveLD. Liver function and hepatotoxicity in cancer. Chapter 151. In: HollandJF, FreiE, BastRCJr, et al. (eds). Cancer Medicine, 5th ed. Hamilton, Ontario, Canada: B.C. Decker Inc; 2000.

101. GilesFJ, KantarjianHM, KornblauSM, et al.Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer2001;92:406. CrossRef

102. TackDK, LetendreL, KamathPS, et al.Development of hepatic veno‐occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant2001;28:895. CrossRef

103. RajvanshiP, ShulmanHM, SieversEL, et al.Hepatic sinusoidal obstruction following Gemtuzumab Ozogamicin (Mylotarg®). Blood2002;99:2310. CrossRef

104. NeumeisterP, EiblM, Zinke‐CerwenkaW, et al.Hepatic veno‐occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti‐CD33 calicheamicin (CMA‐676) immunoconjugate. Ann Hematol2001;80:119. CrossRef

105. CzaudernaP, KatskiK, KowalczykJ, et al.Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg2000;10:300. CrossRef

106. TorneselloA, PiciacchiaD, MastrangeloS, et al.Veno‐occlusive disease of the liver in right‐sided Wilms' tumours. Eur J Cancer1998;34:1220. CrossRef

107. WadleighM, RichardsonPG, ZahriehD, et al.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno‐occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood2003;102:1578. CrossRef

108. LeeJL, GooleyT, BensingerW, et al.Veno‐occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant1999;5:306. CrossRef

109. McDonaldGB. Liver disease of uncertain cause. Bone Marrow Transplant2004;33:977. CrossRef

110. ShulmanHM, GooleyT, DudleyMD, et al.Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation1995;59:1015. CrossRef

111. CordonnierC, MauryS, EsperouH, et al.Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant2005;36:649. CrossRef

112. HoganWJ, MarisM, StorerB, et al.Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood2004;103:78. CrossRef

113. LocasciulliA, BacigalupoA, AlbertiA, et al.Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation1989;48:68. CrossRef

114. SalingerDH, McCuneJS, RenAG, et al.Real‐time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res2006;12:4888. CrossRef

115. McDonaldGB, McCuneJS, BatchelderA, et al.Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther2005;78:298. CrossRef

116. GrochowLB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol1993;20:18.

117. DemirerT, BucknerCD, AppelbaumFR, et al.Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant1996;17:491.

118. HassanM, EhrssonH, LjungmanP. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma1996;22:395. CrossRef

119. VaughanWP, CareyD, PerryS, et al.A limited sample strategy for pharmacokinetic therapy with intravenous busulfan. Biol Blood Marrow Transplant2002;8:619. CrossRef

120. McCuneJS, GibbsJP, SlatteryJT. Plasma concentration monitoring of busulfan. Does it improve clinical outcome?Clin Pharmacokinet2000;39:155. CrossRef

121. MéresseV, HartmannO, VassalG, et al.Risk factors for hepatic veno‐occlusive disease after high‐dose busulfan‐containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant1992;10:135.

122. RuutuT, ErikssonB, RemesK, et al.Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood2002;100:1977. CrossRef

123. TayJ, TinmouthA, FergussonD, et al.Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno‐occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2007;13:206. CrossRef

124. AzoulayD, CastaingD, LemoineA, et al.Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno‐occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant2000;25:987. CrossRef

125. RajvanshiP, McDonaldGB. Expanding the use of transjugular intrahepatic portosystemic shunts for veno‐occlusive disease. Liver Transpl2001;7:154. CrossRef

126. ZenzT, RössleM, BertzH, et al.Severe veno‐occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation‐ role of transjugular intrahepatic portosystemic shunt (TIPS). Liver2001;21:31. CrossRef

127. CarrerasE, BertzH, ArceseW, et al.Incidence and outcome of hepatic veno‐occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood1998;92:3599.

128. GanemG, Saint‐Marc GirardinMF, KuentzM, et al.Venocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Biol Phys1988;14:879. CrossRef

129. McDonaldGB, SharmaP, MatthewsDE, et al.The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation1985;36:603. CrossRef

130. BearmanSI. The syndrome of hepatic veno‐occlusive disease after marrow transplantation. Blood1995;85:3005.

131. HillaireS, BonteE, DenningerMH, et al.Idiopathic non‐cirrhotic intrahepatic portal hypertension in the West: a re‐evaluation in 28 patients. Gut2002;51:275. CrossRef

132. IbarrolaC, ColinaF. Clinicopathological features of nine cases of non‐cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology2003;42:251. CrossRef

133. NakanumaY, HosoM, SasakiM, et al.Histopathology of the liver in non‐cirrhotic portal hypertension of unknown aetiology. Histopathology1996;28:195. CrossRef

134. WanlessIR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology1990;11:787. CrossRef

135. ShimamatsuK, WanlessIR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology1997;26:343. CrossRef

136. DillMT, RothweilerS, DjonovV, et al.Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology2012;142:967. CrossRef

137. NakanumaY, OhtaG, SasakiK. Nodular regenerative hyperplasia of the liver associated with polyarteritis nodosa. Arch Pathol Lab Med1984;108:133.

138. YoungID, SeguraJ, FordPM, et al.The pathogenesis of nodular regenerative hyperplasia of the liver associated with rheumatoid vasculitis. J Clin Gastroenterol1992;14:127. CrossRef

139. SchoutenJN, NevensF, HansenB, et al.Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long‐term cohort study. Aliment Pharmacol Ther2012;35:1424. CrossRef

140. SchoutenJN, Garcia‐PaganJC, VallaDC, et al.Idiopathic noncirrhotic portal hypertension. Hepatology2011;54:1071. CrossRef

141. ChangPE, MiquelR, BlancoJL, et al.Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol2009;104:1707. CrossRef

142. SeijoS, ReverterE, MiquelR, et al.Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis2012;44:855. CrossRef

143. ScoazecJY, MarcheC, GirardPM, et al.Peliosis hepatis and sinusoidal dilation during infection by the human immunodeficiency virus (HIV). An ultrastructural study. Am J Pathol1988;131:38.

144. GoerdtS, SorgC. Endothelial heterogeneity and the acquired immunodeficiency syndrome: a paradigm for the pathogenesis of vascular disorders. Clin Investig1992;70:89. CrossRef

145. LeongSS, CazenRA, YuGS, et al.Abdominal visceral peliosis associated with bacillary angiomatosis. Ultrastructural evidence of endothelial destruction by bacilli. Arch Pathol Lab Med1992;116:866.

146. KimSH, LeeJM, KimWH, et al.Focal peliosis hepatis as a mimicker of hepatic tumors: radiological‐pathological correlation. J Comput Assist Tomogr2007;31:79. CrossRef

147. IannacconeR, FederleMP, BrancatelliG, et al.Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol2006;187:W43. CrossRef

148. McDonaldGB, SharmaP, MatthewsDE, et al.Veno‐occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology1984;4:116. CrossRef